HomeCompareOCX vs MO

OCX vs MO: Dividend Comparison 2026

OCX yields 62.50% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCX wins by $658.2K in total portfolio value
10 years
OCX
OCX
● Live price
62.50%
Share price
$3.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$735.9K
Annual income
$177,443.13
Full OCX calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — OCX vs MO

📍 OCX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCXMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCX + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCX pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCX
Annual income on $10K today (after 15% tax)
$5,312.50/yr
After 10yr DRIP, annual income (after tax)
$150,826.66/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, OCX beats the other by $126,203.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCX + MO for your $10,000?

OCX: 50%MO: 50%
100% MO50/50100% OCX
Portfolio after 10yr
$406.8K
Annual income
$103,205.83/yr
Blended yield
25.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

OCX
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Price Target
$8.06
+151.9% upside vs current
Range: $4.25 — $10.00
Altman Z
-27.0
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCX buys
0
MO buys
0
No recent congressional trades found for OCX or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCXMO
Forward yield62.50%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$735.9K$77.7K
Annual income after 10y$177,443.13$28,968.54
Total dividends collected$614.9K$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$8.06$61.25

Year-by-year: OCX vs MO ($10,000, DRIP)

YearOCX PortfolioOCX Income/yrMO PortfolioMO Income/yrGap
1← crossover$16,950$6,250.00$10,558$768.31+$6.4KOCX
2$28,037$9,900.70$11,352$1,015.87+$16.7KOCX
3$45,305$15,305.49$12,482$1,367.86+$32.8KOCX
4$71,591$23,114.13$14,103$1,883.39+$57.5KOCX
5$110,737$34,135.17$16,472$2,664.91+$94.3KOCX
6$167,835$49,346.36$20,024$3,897.79+$147.8KOCX
7$249,481$69,897.34$25,537$5,933.74+$223.9KOCX
8$364,047$97,102.68$34,478$9,476.77+$329.6KOCX
9$521,955$132,424.34$49,776$16,022.63+$472.2KOCX
10$735,935$177,443.13$77,699$28,968.54+$658.2KOCX

OCX vs MO: Complete Analysis 2026

OCXStock

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Full OCX Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this OCX vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCX vs SCHDOCX vs JEPIOCX vs OOCX vs KOOCX vs MAINOCX vs PMOCX vs BTIOCX vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.